Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):431-2. doi: 10.1097/QAI.0b013e3181b08f09.
No abstract available

Publication types

  • Historical Article
  • Letter

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / pharmacokinetics
  • Adenine / therapeutic use
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / blood
  • Anti-HIV Agents / therapeutic use
  • Atazanavir Sulfate
  • Drug Interactions
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • History, 17th Century
  • Humans
  • Male
  • Oligopeptides / administration & dosage*
  • Oligopeptides / blood
  • Oligopeptides / pharmacokinetics
  • Oligopeptides / therapeutic use*
  • Organophosphonates / administration & dosage*
  • Organophosphonates / pharmacokinetics
  • Organophosphonates / therapeutic use*
  • Pyridines / administration & dosage*
  • Pyridines / blood
  • Pyridines / pharmacokinetics
  • Pyridines / therapeutic use*
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Oligopeptides
  • Organophosphonates
  • Pyridines
  • Atazanavir Sulfate
  • Tenofovir
  • Adenine